SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CBD Life Sciences Inc. (CBDL) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 34/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CBDL
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio12.54
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$-2,405.14 |
$0.00 |
$-156.33K |
- |
| 2013 |
$-2,294.59 |
$155.55K |
$-367.14K |
-236% |
| 2014 |
$-428.18 |
$122.79K |
$-780.14K |
-635.3% |
| 2019 |
$-0.01 |
$79.64K |
$-861.01K |
-1081.2% |
| 2020 |
$0.00 |
$225.9K |
$-1.69M |
-750.1% |
| 2021 |
$0.00 |
$59.26K |
$-5.13M |
-8654.2% |
| 2022 |
$0.00 |
$160.24K |
$-859.8K |
-536.6% |
| 2023 |
$0.00 |
$167.15K |
$-78.57K |
-47% |
| 2024 |
$0.00 |
$108.89K |
$-757.19K |
-695.4% |
| 2025 |
$0.00 |
$98.32K |
$-48.93K |
-49.8% |
